In today's economic landscape, where inflation and rising interest rates are a constant concern, companies are compelled to prioritize efficiency and cash flow management. This focus is essential not ...
In the study, a once-daily, single-tablet combination of bictegravir and lenacapavir was as effective as Gilead's existing ...
By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...
Clinical Trials Arena on MSN
Gilead’s HIV ART combo deemed non-inferior in second phase III trial
Gilead Sciences’ human immunodeficiency virus (HIV) single-tablet combination antiretroviral therapy (ART) has proven ...
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...
BlackRock Health Sciences Trust is a Buy for income investors, offering an 8% yield, NAV discount, and resilient healthcare ...
Arcus Biosciences Inc. and partner Gilead Sciences Inc. are scrapping phase III work with anti-TIGIT antibody domvanalimab after an independent data monitoring committee said the drug will fail in ...
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC ...
Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning the company to launch the ...
Dec 12 () - Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback